In addition, in patients with pretreated, relapsed metastatic HER2-negative breast cancer, the new CXCR4 antagonist balixafortide (POL6326, NCT01837095, phase 1) was evaluated in combination with eribulin.213. This evidence concerns the gene CXCR4 and breast carcinoma.